An FDA advisory panel has voted in favor of moving hydrocodone combination products, including Vicodin, Lortab and Norco, into the more restrictive Schedule II category of controlled substances, according to a report by The Clinical Advisor.
Moving the drugs to Schedule II category would eliminate a clinician's ability to give out a six-month prescription of the drugs. Also, calling in for a prescription of the drugs would no longer be possible.
Despite the majority decision, it remains to be seen how the FDA will interpret the advisory panel's recommendations, according to the report.
New Rules, Prescription Monitoring Lower Overdose Death Rate by 23% in Washington
Nevro Receives 4 Patents for Chronic Pain Device
Moving the drugs to Schedule II category would eliminate a clinician's ability to give out a six-month prescription of the drugs. Also, calling in for a prescription of the drugs would no longer be possible.
Despite the majority decision, it remains to be seen how the FDA will interpret the advisory panel's recommendations, according to the report.
More Articles on Pain Management:
Floyd County Considers Pain Clinic MoratoriumNew Rules, Prescription Monitoring Lower Overdose Death Rate by 23% in Washington
Nevro Receives 4 Patents for Chronic Pain Device